Dynamic PET/CT scan of 68Ga-FAPI-04 for the optimal acquisition time in suspected malignant hepatic cancer patients
- PMID: 36583752
- DOI: 10.1007/s00261-022-03764-2
Dynamic PET/CT scan of 68Ga-FAPI-04 for the optimal acquisition time in suspected malignant hepatic cancer patients
Abstract
Purpose: Dynamic PET/CT scan of 68Ga-FAPI-04 in patients with suspected malignant hepatic lesions were retrospectively analyzed to find the optimal acquisition time with better lesion detection rate.
Methods: Twenty-two patients with lesions confirmed by CT or MRI were performed with dynamic 68Ga-FAPI-04 PET/CT scan. Tracer uptake of lesions and normal organs at different time points were analyzed. Standardized uptake value (SUV) and tumor-to-background (TBR) were calculated based on the quantification of images.
Results: SUV of normal organs decreased rapidly from 10 to 30 min and decreased gradually from 30 to 60 min. Besides, the uterus showed a particularly high uptake in all patients (12.62 ± 4.58 at 10 min p.i., 12.04 ± 3.99 at 30 min p.i., 10.92 ± 2.38 at 60 min p.i.). SUV of lesions decreased gradually, while TBR increased from 10- to 60-min post-injection. Visual analysis verified a comparable lesion detectability of 30 min and 60 min with images of 10 min showing a decreased lesion detection number.
Conclusion: This study revealed that similar detection rates were achieved at both 30 and 60 min, suggesting a static scan at 30 min to be appropriate in the clinic. Besides, although with high lesion uptake, early 68Ga-FAPI-04 PET imaging at 10 min after tracer injection could cause missed lesion detection.
Keywords: 68Ga-FAPI-04; Dynamic scan; Hepatic cancer; Positron emission tomography/computed tomography.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
The earliest optimal timing for total-body 68Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study.Eur Radiol. 2024 Jul;34(7):4550-4560. doi: 10.1007/s00330-023-10264-4. Epub 2023 Dec 18. Eur Radiol. 2024. PMID: 38110627
-
[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04.Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2833-2843. doi: 10.1007/s00259-021-05646-z. Epub 2021 Dec 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 34893920
-
Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas.Sci Rep. 2023 Oct 19;13(1):17848. doi: 10.1038/s41598-023-43049-2. Sci Rep. 2023. PMID: 37857656 Free PMC article.
-
Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions.J Nucl Med. 2022 Dec;63(12):1844-1851. doi: 10.2967/jnumed.122.264069. Epub 2022 May 26. J Nucl Med. 2022. PMID: 35618480 Free PMC article.
-
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers.Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931. doi: 10.1007/s00259-020-05132-y. Epub 2020 Nov 26. Eur J Nucl Med Mol Imaging. 2021. PMID: 33244617
Cited by
-
Artificial intelligence in fracture detection on radiographs: a literature review.Jpn J Radiol. 2025 Apr;43(4):551-585. doi: 10.1007/s11604-024-01702-4. Epub 2024 Nov 14. Jpn J Radiol. 2025. PMID: 39538068 Review.
-
Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review.Int J Mol Sci. 2024 Jun 29;25(13):7197. doi: 10.3390/ijms25137197. Int J Mol Sci. 2024. PMID: 39000301 Free PMC article. Review.
-
Feasibility of a deep learning algorithm to achieve the low-dose 68Ga-FAPI/the fast-scan PET images: a multicenter study.Br J Radiol. 2023 Sep;96(1149):20230038. doi: 10.1259/bjr.20230038. Epub 2023 Jul 3. Br J Radiol. 2023. PMID: 37393527 Free PMC article.
-
Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.Radiol Med. 2023 Apr;128(4):393-401. doi: 10.1007/s11547-023-01614-9. Epub 2023 Mar 21. Radiol Med. 2023. PMID: 36943653
References
-
- Siveke JT (2018) Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment. J Nucl Med 59:1412-4. https://doi.org/10.2967/jnumed.118.214361 . - DOI - PubMed
-
- Hamson EJ, Keane FM, Tholen S, et al (2014) Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl 8:454-63. https://doi.org/10.1002/prca.201300095 . - DOI - PubMed
-
- Giesel FL, Kratochwil C, Lindner T, et al (2019) (68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med 60:386-92. https://doi.org/10.2967/jnumed.118.215913 . - DOI - PubMed - PMC
-
- Meyer C, Dahlbom M, Lindner T, et al (2019) Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med 61:1171-1177. https://doi.org/10.2967/jnumed.119.236786 . - DOI - PubMed
-
- Giesel FL, Heussel CP, Lindner T, et al (2019) FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging 46:1754-5. https://doi.org/10.1007/s00259-019-04346-z . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical